GTL Shortlisted for Cancer Research Horizons New Startup of the Year Award
GTL's AI biomarker platform recognized for its potential to revolutionize cancer diagnosis and treatment.
News and updates
from the frontier in AI biomarkers
Upcoming events
London, UK
Biomarker and Companion Diagnostics Conference - Markets&Markets
Daniel Royston, pathology lead at Ground Truth Labs, to discuss AI-driven analysis of morphological biomarkers for trials in haemato-oncology.
San Diego, USA
ASH Annual Meeting 2024
Presenting our latest research at American Society of Hematology 2024.
Posts
Insights from ASH 2023: Advancements in MPN Research
Ground Truth Labs highlights ASH 2023's innovative MPN therapies and advances AI-driven fibrosis assessment to revolutionize treatment approaches.
VP Business Development
MPN Hub discusses AI in the future of bone marrow histopathology
Daniel Royston, pathology lead at Ground Truth Labs, discusses the role of AI in bone marrow histology with MPN Hub.
Pathology Lead
Recognising blood cancer awareness month 2023
The vital role of novel research and development in tackling blood cancers like myeloproliferative neoplasms and myeloma.
AI biomakers to transform oncology
AI biomarkers will transform oncology with new maps for tumor biology and breakthrough predictors for treatment response. We have the opportunity to improve outcomes for every cancer patient with AI-driven insights from digital pathology.
Co-founder
GTL raises $4.3M to launch commercially with AI biomarkers
Today, Ground Truth Labs (GTL), is thrilled to announce its launch into the wider healthtech space. Backed by a $4.3M funding round led by Oxford Science Enterprises